Clinical trials
Breast Cancer Female clinical trials
Below are recruiting breast cancer female clinical trials, each written for real people, not researchers. We’re tracking 1,100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07803081Recruiting
Radiotherapy after breast surgery without lymph node biopsy
This study looks at how well radiation therapy works for women with early-stage breast cancer who had breast-conserving surgery but did not have their underarm lymph nodes removed. It aims to understand long-term outcomes and help guide future treatment decisions.
SeoulAges 19 years+ - NCT07808086Recruiting
Tumor bacteria in triple-negative breast cancer treatment response
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
PaviaAges 18 years+ - NCT06236269RecruitingPhase 2
Sacituzumab Govitecan for HR+/HER2- advanced breast cancer
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Badalona, BarcelonaAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT07796880RecruitingPhase 2
Study of a new drug with hormone therapy before breast cancer surgery
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
Guangzhou, GuangdongAges 18–70 - NCT07798466Enrolling by invitation
Immediate breast reconstruction and radiation timing after breast cancer surgery
This trial studies whether getting radiation therapy right after breast reconstruction surgery is safe and effective for women with invasive breast cancer who had chemotherapy before surgery. It aims to improve outcomes and quality of life for patients needing both treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07782814Recruiting
A study of a new breast scan for breast tissue evaluation
This study tests a new, non-invasive scanning tool that uses harmless electrical signals to look at breast tissue. It may help doctors evaluate breast conditions without surgery, which could be useful for diagnosis or monitoring treatment.
LondonAges 18–85 - NCT07768436RecruitingPhase 2
cmf chemotherapy for breast cancer in older adults
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
Basking Ridge, New JerseyAges 70 years+ - NCT03827317Recruiting
Scan to see HER2 in breast cancer with a new tracer
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
LondonAges 18 years+ - NCT07766018RecruitingPhase 2
Elacestrant for advanced or metastatic breast cancer
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
ChibaAges 18 years+ - NCT06331169RecruitingPhase 1
Testing anlotinib plus trastuzumab deruxtecan for advanced breast cancer
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05772390RecruitingPhase 2
Second radiation for a small breast cancer return
This Phase 2 study tests whether giving targeted radiation again to the same breast can control a small, local breast cancer that came back after prior whole-breast radiation. It may help some patients avoid or delay further treatment for the breast while carefully checking safety.
Meldola, Forlì CesenaAges 18 years+ - NCT07752238Recruiting
Predicting outcomes for newly diagnosed metastatic breast cancer
This study uses information from women with newly diagnosed breast cancer that has spread (metastatic) to create a tool that helps predict how the disease may progress. By looking at your medical records, they hope to improve care and help future patients.
Szombathely, Vas CountyAges 18 years+ - NCT07732491RecruitingPhase 2
Culmerciclib for HR+ HER2+ advanced breast cancer
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05594095RecruitingPhase 2
Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07723209Recruiting
Radiation after no lymph node sampling in breast cancer
This trial tests whether radiation therapy alone is safe and effective for women 40 and older with early-stage breast cancer who have not had lymph node sampling. It aims to simplify treatment while maintaining good outcomes.
New York, New YorkAges 40 years+ - NCT07718841Recruiting
Blood test monitoring for early-stage breast cancer
This study uses a simple blood test called liquid biopsy to monitor cancer DNA in people with early-stage breast cancer before and during treatment. The goal is to see if this test can help guide treatment and improve outcomes.
San Sebastián, GuipúzcoaAges 18 years+ - NCT05935150Recruiting
Skipping lymph node surgery in early breast cancer
This trial studies whether you can safely avoid a lymph node biopsy in the armpit for early breast cancer when scans and exams look negative. It may reduce surgery-related side effects while still keeping cancer care on track.
Nanjing, JiangsuAges 18–70 - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07702708Recruiting
AI predicts chemotherapy response in HR+/HER2- breast cancer
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Fuzhou, FujianAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07695259RecruitingPhase 4
Olaparib with trastuzumab and pertuzumab for older women with HER2+ breast cancer
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
Hangzhou, ZhejiangAges 60 years+ - NCT04289935Recruiting
Vacuum biopsy before surgery to check treatment response
This trial studies a special vacuum-assisted biopsy taken just before breast surgery to see how well pre-surgery (neoadjuvant) chemotherapy worked. It may help doctors understand whether patients truly had a complete or near-complete response on scans, which can guide next steps.
SalzburgAges 18 years+ - NCT03788213Recruiting
Shorter vs longer radiation after breast cancer surgery
This trial compares giving breast radiation over one week versus three weeks after surgery. It aims to see whether the shorter schedule works just as well and is safe for people with certain types of early breast cancer.
Kolkata, West BengalAges 18 years+
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer female?
- Yes. Clin2 currently lists 1,100 recruiting breast cancer female studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer female trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer female trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.